The Jewellery Boom, Explained
As major luxury brands struggle to maintain momentum amid an industry-wide slowdown, one category is bucking the trend: jewellery. While demand for handbags and apparel softens, fine jewellery sales continue to rise, driven by consumer desire for lasting value, emotional resonance and self-expression.
Simone Stern Carbone and Joan Kennedy join The Debrief to discuss how independent jewellers are thriving with creativity and personality, the rising popularity of novelty pieces, and why jewellery is uniquely positioned to attract buyers in today's luxury market. Key Insights: Despite slowing luxury sales, jewellery sales have continued to boom. As Stern Carbone notes, consumers perceive luxury jewellery as an inherently safer investment. She says, 'Instinctively, a lot of people associate jewellery – especially if it's got gold, gemstones or diamonds – with something you would dish out more money for more readily than for a handbag potentially made out of nylon.'
While big jewellery brands are growing, smaller competitors are booming as they foster deep customer relationships and maintain flexible, manageable supply chains. Stern-Carbone highlights, 'Jewellery is so personal. When you have a very distinct aesthetic, you really connect with your customers long term, potentially for life. This is a really personal relationship that smaller brands can capitalise on.'
Kennedy emphasises that modern jewellery marketing resonates by being accessible and relatable. 'One designer I spoke to puts her charm necklaces next to candy necklaces, so that feels fun,' she says. 'A lot of these designers are doing things that are very lo-fi. It's like a picture of a wrist on Instagram. And then they reply to DMs, like, 'Hey, show me that bracelet with something else.' So the way that they present it is also really relevant to shoppers, versus the very high-gloss and traditional style of high jewellery.'
Novelty jewellery began gaining popularity post-Covid. 'People were buying camp jewellery, but they were paying $50 for a funky, colourful ring. And then more recently, people are like, okay, let's bring in the value piece of this,' says Kennedy. Novelty jewellery has surged as consumers seek personal expression in response to uniform dressing and quiet luxury trends. Kennedy continues, 'You're leaning into things that are uniform dressing, so how do we spice that up? Let's go for more novelty in jewellery.' Additional Resources:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
43 minutes ago
- Miami Herald
Large fashion retailer closes stores amid alarming customer trend
Did you see headlines saying every 10 minutes one store closes in the United States? While there's no real data to confirm the attention-grabbing headline, considering the number of recent closures, it does sound plausible. If true, it signals a major retail crisis. Don't miss the move: Subscribe to TheStreet's free daily newsletter Why are retailers having such a hard time? Many of them, even large chains, are not being able to deal with the current economic challenges, as they are yet recovering from the disaster that the Covid pandemic brought upon them. So many brick-and-mortar stores were swiped by the pandemic, and what's worse, even before Covid, they had been struggling to survive the so-called "Amazon effect." Both smaller operators and large national chains are dealing with persistent inflation and increasing rates on debt obligations. It is projected that more than 15,000 stores across the country will shut their doors this year, which is more than double the number that closed last year. Among the biggest names that have recently closed multiple stores or even gone bankrupt are CVS, Kohl's, Walmart, JCPenney, At Home, GameStop, Macy's Rite Aid, Joann, and many more. That's right - all kinds of retailers and businesses are impacted by these challenging times, from popular and luxury brands, to department stores, to grocery and supermarket chains. All of them are fighting to survive. Taking all this into account, it's no surprise that one iconic mall retailer has closed two more stores. Image source: Shutterstock Nordstrom has a huge base of loyal customers for several reasons, among which consumer-focused experience is the most praised. It places a lot of effort on making service one of its strongest points, which seemed to have benefited both the company and customers. The fashion giant is often lauded for its personalized shopping experience, customer-centric culture, and amazingly generous return policy. It's often mentioned on social media, with fans claiming the retailer is extremely flexible, making every return hassle-free. Related: Largest office supply retailer closing stores, no bankruptcy Nordstrom now operates around 350 stores, but it all started back in 1901 when the first shoe store opened at Fourth and Pike in Seattle. That's right, the first one was a shoe store. John W. Nordstrom, a young and hardworking immigrant from Sweden, worked in mines, went to Alaska in search of gold, and then was offered and accepted a partnership by Seattle shoemaker Carl F. Wallin. More Retail: Huge retail chain suddenly closing hundreds of storesMajor retailer scores huge benefit from Joann bankruptcyHome Depot, Target, Ulta and more strike back at retail crime The business grew, and by 1960, the Seattle shoe shop became the biggest across the nation, running eight locations in Washington and Oregon. In 1971, the company went public, and two years later, Nordstrom was recognized as the biggest fashion specialty store on the West Coast. Despite its capacity and customer loyalty, Nordstrom is not immune to the current economic challenges and alarming customer trends, which is why over the last five years, it has closed more than a dozen stores. Nordstrom's latest store to close after nearly 15 years is the one at Santa Monica Place, California. Related: Costco brings back controversial perk, dividing loyal shoppers "We believe we'll be best able to serve customers in the area by leveraging our surrounding stores and through our digital channels," Nordstrom said in a statement, according to 4NBC Los Angeles. The three-level store, often praised for its location, which is two blocks from the beach, will have its last business day on August 26. Nordstrom has not yet revealed how many people might lose their jobs, but added it will help them find another position within the company. Earlier in June, Nordstrom confirmed it would close another of its mall locations this summer. It is the store inside the Saint Louis Galleria in Richmond Heights, Missouri. A Nordstrom spokesperson shared that the closure is part of a wider strategy to focus on nearby locations and digital operations, reported 5 On Your Side. About 135 employees should be impacted by the closure of the Galleria locations, and some of them will have a chance to transfer to other Nordstrom stores. Nordstrom also operates two Nordstrom Rack stores in the St. Louis region, one at 1585 South Brentwood Blvd. in Brentwood, and another at 100 Highlands Blvd. Drive in Manchester. Related: Amazon shuts down another key business location The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
an hour ago
- Yahoo
Royal Caribbean Cruises Jumps Into the Top 100 Stocks to Buy. Should You Bite?
The shortened trading week due to the Fourth of July holiday on Friday started strong on Monday, with the S&P 500 closing at a record high, generating a 10.57% return in the second quarter. One of the stocks benefiting from the index's 0.52% gain yesterday was Royal Caribbean Cruises (RCL), one of the world's largest cruise operators. RCL stock was up 1.2% on the day, jumping into Barchart's Top 100 Stocks to Buy, in the 87th spot. Elon Musk's Tesla Makes History With 'First Time That a Car Has Delivered Itself to Its Owner' This Defense Stock Could Be the Next Palantir. Should You Buy It Now? Cathie Wood Is Pounding the Table on AMD Stock. Should You Buy Shares Now? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. In the past year, Royal Caribbean's stock has gained over 100%, hitting 52-week highs on 46 occasions. As I write this on Tuesday morning, RCL stock is trading above $316, poised to set an all-time high. Times have changed significantly since hitting a 10-year low of $19.25 in March 2020, driven entirely by a global shutdown in travel due to the COVID-19 pandemic. I've been a long-time bull when it comes to cruise stocks generally--and Royal Caribbean Cruises specifically. I like the way it operates its business. I don't see cruising slowing down without an outside economic or health-related situation slowing it down. That said, it has never traded higher, and while it has significant momentum—up 21% in the past month alone—its valuation is moving into nosebleed territory. The FOMO (fear of missing out) on RCL is high. Should you bite and buy some of its stock? Here are the pros and cons of doing so. In one word: Valuation. It ain't cheap. Analysts expect it to earn $15.42 a share in 2025 and $17.66 in 2026. At its current share price of $316.99, it trades at 20.6 times its forward 2025 EPS and 17.9 times its forward 2026 EPS. The bullish argument you can make is that this multiple isn't excessive compared to the S&P 500, which currently trades at 21.9x its 2026 forward earnings. Before the pandemic, RCL stock had never traded above $150, with a forward EPS multiple no higher than 15.36x (as of the end of 2017), according to S&P Global Market Intelligence. How do analysts feel about RCL stock? Of the 24 covering RCL, 19 rate it a Buy (4.54 out of 5), so it's highly regarded by Wall Street. However, the mean target price is $275, 13% lower than its current share price. Another potential negative aspect of RCL stock beyond valuation is the price of oil. It's been relatively benign over the past few years, with a barrel of West Texas Intermediate (WTI) hitting a five-year high of $114.84 in May 2022. Since then, it has fallen to $62.50 as of May. Adjusted for inflation, it's fallen by half. Oil prices account for a significant chunk of every cruise line's operating expenses. In 2022, Royal Caribbean paid out $1.07 billion for fuel, representing a 178% increase from the amount paid in 2021. In 2024, it paid out $1.16 billion, which isn't a substantial increase considering the additional revenue generated. However, in 2024, fuel accounted for 7.0% of its revenue, compared to over 12% in 2022. That was the difference between an operating margin of 24.9% in 2024 and -8.2% in 2022. While it doesn't look like the Iran/Israel/US situation is going to spin out of control, if it does, oil prices are sure to rise over $100 in no time. That's never good news for cruise stocks. If oil prices hit $100 a barrel, you can be sure Royal Caribbean's ability to deliver $17.66 in earnings per share in 2026 won't be doable. As Clint Eastwood said in Dirty Harry, 'Do ya feel lucky, punk? Well, do ya?' The trend remains your friend, and I'm not talking about the stock's momentum, but rather the ongoing demand for cruising. It's off the charts. Back in June 2023, I suggested that cruise stocks remained a Buy. 'If the demand keeps up for the next 12-24 months and it gets its operating margins back to where they were pre-pandemic, $94 will appear very cheap for RCL stock,' I wrote in 2023. 'Whether you're looking at RCL, CCL, or NCLH, their stocks have more room to run in the second half of 2023.' Royal Caribbean's stock has gained 237% in the 24 months since, suggesting I wasn't the only one who felt the cruise operator's stock had room to run. And run it did. Is it too late to buy? Maybe. However, barring a major flare-up in the Middle East, the demand for cruising remains high, as does profitability. The company reported strong Q1 2025 earnings at the end of April, including an upward revision to its annual guidance. It now expects to grow its earnings per share to $15.05 at the midpoint of its guidance, from a 3.5% increase in net yield. The net yield is revenue generated per available cruise day, after accounting for commissions, transportation, and other cruise-related expenses. The 3.5% increase is in addition to an 11.6% increase in 2024. 'Bookings for 2025 have remained on track, cancellation levels are normal, and we continue to see excellent close-in demand," said Jason Liberty, Royal Caribbean's CEO, in the company's April 29 press release. If you do buy a cruise stock, Royal Caribbean is the best option among them. If you need the money in a year for your kid's college education, I wouldn't risk it. However, if you are willing to put aside some dry powder to buy more should RCL stock hit a rough patch in the next year, it's one of the best S&P 500 stocks to own for the long haul. I write a fair bit about options. They're an inexpensive way to bet on RCL's stock moving higher over the next 6-12 months. The simplest move would be to buy a call deep OTM (out of the money) like the June 18/2026 $410, which will cost you $19.50, or 6.12% of its stock price. If the share price at expiration is above $429.50 (38.55% higher), you'll, at worst, break even on the bet, and if it closes much higher than that, you'll profit nicely from the difference between the share price and the lower strike price. Worst-case scenario, its share price goes nowhere, and it expires worthless. However, should it move higher, but not quite to the breakeven point of $429.50, you could sell the option before it expires to recover some of your net debit, thereby reducing your loss on the trade. Will RCL stock be over $429.50 by next June? I'd be shocked if it were, despite my belief that it's an excellent long-term investment. On the date of publication, Will Ashworth did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
New York Post
an hour ago
- New York Post
Pfizer scientist subpoenaed over claims COVID vax testing was ‘deliberately' slowed before 2020 election
WASHINGTON — A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that senior executives at the pharma giant colluded to 'deliberately slow down' clinical tests of its COVID-19 vaccine ahead of the 2020 presidential election. The House Judiciary Committee ordered Dr. Philip Dormitzer, the ex-vice president and chief scientific officer of RNA and viral vaccines for Pfizer, to appear for a deposition on July 22 after demanding answers about allegations 'that senior Pfizer executives conspired to withhold public health information so as to influence the 2020 presidential election.' 'To date, you have failed to voluntarily comply with our requests,' wrote Judiciary Chairman Jim Jordan (R-Ohio). 'Therefore, the Committee must resort to compulsory process to obtain your testimony and the requested documents.' 4 The House Judiciary Committee ordered Dr. Philip Dormitzer, the ex-vice president and chief scientific officer of RNA and viral vaccines for Pfizer, to appear for a deposition on July 22. Bloomberg via Getty Images In a May 29 letter to the Judiciary panel, Dormitzer attorney Susan Brune indicated that her client did not have any relevant records and promised 'Pfizer's representatives are or will be in communication … to provide whatever details you might request.' Jordan's panel wrote to Pfizer's chairman and CEO, Dr. Albert Bourla, in May asking for emails, texts, meeting notes and other documents showing any data from the clinical trials or communications with federal public health agencies. Brune and reps for Pfizer did not immediately respond to requests for comment. 4 Dormitzer has previously denied that he or anyone at Pfizer tried to delay the vaccine. Getty Images The London-based drugmaker GSK had first revealed the purported conspiracy to Jordan in an April 16 letter, claiming that Dormitzer had asked to be relocated outside the US in November 2024 'due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine.' Asked why he wanted to move, Dormitzer told the GSK employee: 'Let's just say it wasn't a coincidence, the timing of the vaccine.' Dormitzer also disclosed to other GSK employees 'in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year,' according to the letter to Jordan. 4 Pfizer's COVID vaccine results, first reviewed by independent experts for effectiveness and safety, were shared by its team of scientists just five days after polls closed for the 2020 election on Nov. 3. REUTERS Notably, GSK denied that Dormitzer was admitting to intentionally 'delaying disclosure of completed results,' but described it as 'a situation of slowing down results before disclosure became necessary.' Pfizer's COVID vaccine results, first reviewed by independent experts for effectiveness and safety, were shared by its team of scientists just five days after polls closed for the 2020 election on Nov. 3. Media outlets called the race for former President Joe Biden on Nov. 7. Dormitzer has previously denied that he or anyone at Pfizer tried to delay the vaccine rollout, and said his comments to his colleagues at GSK have been misinterpreted. 4 The London-based drugmaker GSK claimed that Dormitzer had asked to be relocated outside the US in November 2024 'due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine.' REUTERS Dormitzer has only donated to Democratic campaigns, Federal Election Commission (FEC) filings show, shelling out hundreds of dollars in the 2010s to congressional candidates while working in vaccine development at Novartis. Manhattan prosecutors first unearthed the bombshell allegations about the vaccine trials as part of a federal investigation into Pfizer. 'The COVID-19 vaccine development process was driven by science and guided by the U.S. FDA back in 2020,' a rep for the company previously said in a statement. 'We have consistently and transparently reiterated the facts and the timeline of the tireless work of scientists, regulators, and thousands of clinical trial volunteers who made the vaccine possible. Theories to the contrary are simply untrue and being manufactured.'
